Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

First International Summit on Interventional Pharmacoeconomics

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Deborah Collyar: What's In It for Patients?

Issues in Oncology

The ASCO Post Staff

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Jun

Today In Oncology

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Related Videos

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Deborah Collyar: What's In It for Patients?

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

I Miss My Life

AACR Cancer Disparities Progress Report Mortality Rates Improve But Care Inequities Persist

Fertility Preservation Access Remains Limited and Unequal for Many Girls and Young Women With Cancer

Adverse Events With CD3-Based T-Cell–Engaging Bispecific Antibody Treatment in Cancer

Survey Results Show Patients Prefer Learning of a Diagnosis From Their Doctor Rather Than a Health Portal